Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Ac Immune SA has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 6 distinct examiners in 6 distinct art units. DONOHUE, SEAN R is the busiest examiner, with 1 pending matter, so the pending activity is distributed across separate examination channels.
The one-to-one examiner and art-unit pattern favors centralized docket oversight combined with application-level prosecution plans. Counsel should harmonize biotechnology and pharmaceutical terminology, but should not assume that one examiner’s treatment will apply across the portfolio. Each response can be reviewed for consistent support and claim architecture while addressing the particular cited record and procedural posture.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708739 | DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS | DONOHUE, SEAN R | — |
| 18650535 | Anti-Abeta Therapeutic Vaccines | KIM, YUNSOO | — |
| 18222115 | NOVEL COMPOUNDS | LEE, CHIHYI NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039840 | Antibody Delivery | MCCORMICK, CATHERINE LYNN | 26d |
| 18708739 | DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS | DONOHUE, SEAN R | — |
| 18650535 | Anti-Abeta Therapeutic Vaccines | KIM, YUNSOO | — |
| 18227103 | NOVEL COMPOUNDS | FETTEROLF, BRANDON J | — |
| 18222115 | NOVEL COMPOUNDS | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1641 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708739 | DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS | DONOHUE, SEAN R | 1618 | §103§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18650535 | Anti-Abeta Therapeutic Vaccines | KIM, YUNSOO | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18227103 | NOVEL COMPOUNDS | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18222115 | NOVEL COMPOUNDS | LEE, CHIHYI NMN | 1628 | §102§103§112 | Final Rejection | — | Pending | Jul 14, 2023 |
| 18039840 | Antibody Delivery | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Final Rejection | 26d | Pending | Jun 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAc Immune SA has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Sean R Donohue has the most, with 1 of Ac Immune SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
